title: [Time course changes in morphological and functional characteristics of gastric mucosa after eradication of Helicobacter pylori in duodenal ulcers].
abstract: OBJECTIVE
  To study trends in morphological changes of gastric mucosa (GM) and its functional characteristics (serum gastrin-17, pepsinogens I and II) in eradication of Helicobacter pylori (HP) in patients with duodenal ulcer (DU).
  
  
  METHODS
  HP infection was detected with a rapid urease test, morphological study of gastrobiopsies and polymerase chain reaction in 59 patients with DU. The results of HP eradication were assessed two months after the treatment. Morphological study of gastrobiopsies, assays for gastrin-17, pepsinogens I and II in blood serum were made before the treatment and one year after HP eradication.
  
  
  RESULTS
  By the results of eradication two groups were formed: with effective eradication and uneffective eradication of H. pylori. Examination of GM one year after successful H. pylori eradication in DU patients GM inflammation relieved: reduction in polymorphonuclear (by 42.6%), mononuclear (by 29.3%) infiltration and number of lymphocytic follicules (16.8-fold). GM atrophy decreased by 47.8%. In patients with uneffective eradication the above positive changes were not registered. After H. pylori eradication, serum gastrin-17 lowered by 46. 7%, pepsinogen I--by 30.5%, pepsinogen II--by 36.9%. In uneffective eradication this decrease did not occur.
  
  
  CONCLUSIONS
  H. pylori eradication leads to positive changes in morphological and functional indices reflecting GM condition.
authors.forename: S I
authors.initials: SI
authors.lastname: Pimanov
authors.forename: E V
authors.initials: EV
authors.lastname: Makarenko
authors.forename: A V
authors.initials: AV
authors.lastname: Voropaeva
authors.forename: M E
authors.initials: ME
authors.lastname: Matveenko
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D004269:DNA, Bacterial / Q000032:analysis; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D005755:Gastrins / Q000097:blood; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007413:Intestinal Mucosa / Q000382:microbiology / Q000473:pathology*; D008297:Male; D020116:Pepsinogen A / Q000097:blood; D020115:Pepsinogen C / Q000097:blood; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D004269:DNA, Bacterial; D005755:Gastrins; C013550:gastrin 17; D020115:Pepsinogen C; D020116:Pepsinogen A